Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06665828 | Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults | PHASE1 | COMPLETED | 72 | — | — | Mar 4, 2025 | Jan 29, 2026 | Feb 6, 2026 | 1 | Belgium |
| Arm | Type | Description |
|---|---|---|
| REGN9533 | EXPERIMENTAL | Randomized as described in the protocol Escalating Cohorts including Optional Cohorts |
| Placebo | EXPERIMENTAL | Randomized as described in the protocol |
| Name | Type | Description |
|---|---|---|
| REGN9533 | DRUG | Administered per the protocol |
| Matching Placebo | DRUG | Administered per the protocol. |
Key Inclusion Criteria: 1. Has a body mass index between 18 and 32 kg/m2, inclusive 2. Is judged by the investigator to be in good health based on medical history, physical examination, vital sign measurements, and electrocardiograms (ECGs) performed at screening and/or prior to administration of i...